Foley Partner David Rosen was quoted in an article that appeared in FDA Week on June 24, 2010 titled “OIG, Stakeholders Urge FDA To Clamp Down On Foreign Clinical Trials.” Rosen discusses criticisms directed towards the Food and Drug Administration (FDA) by lawmakers and drug safety advocates for what they view as lackluster oversight of clinical trials conducted abroad. He states that data collected during pivotal trials is likely to come under scrutiny by the FDA, adding that the majority of companies are working hard to ensure that data generated outside the U.S. is of very high quality.
23 February 2024 In the News
Christopher Swift Comments on New U.S. Sanctions Against Russia
Foley & Lardner LLP partner Christopher Swift is quoted in the CBS article, “U.S. issues hundreds of new Russia sanctions over Alexey Navalny's death and war in Ukraine.”
22 February 2024 In the News
Louis Lehot Authors Article on the Business of Space Tourism
Foley & Lardner LLP partner Louis Lehot authored The Recorder article, “An M&A Lawyer's Insight Into Earth's Challenges From Outer Space,” exploring the growing business of space tourism and the plans underway for expanding this novel form of escape.
21 February 2024 In the News
Kate Gehl and Paul Piaskoski Author Article on FTC Approach to AI
Foley & Lardner LLP partner Kate Gehl and associate Paul Piaskoski authored the IP Litigator article, “FTC Weighs in on Threats to Competition from Artificial Intelligence in Comment to U.S. Copyright Office,” exploring the U.S. Federal Trade Commission’s approach to the emerging technology.